Tracon Pharmaceuticals Inc. (NASDAQ:TCON) shares were down 6% on Monday . The company traded as low as $4.62 and last traded at $4.68, with a volume of 61,256 shares trading hands. The stock had previously closed at $4.98.

Separately, Zacks Investment Research downgraded Tracon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 20th.

The firm’s 50-day moving average price is $5.67 and its 200-day moving average price is $6.85. The company’s market capitalization is $57.11 million.

Tracon Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings data on Wednesday, May 11th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.16. Analysts predict that Tracon Pharmaceuticals Inc. will post ($2.55) EPS for the current year.

TRACON Pharmaceuticals, Inc (TRACON) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, age-related macular degeneration (AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.